Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarMMa-4: bb2121 (ide-cel) in High-Risk NDMM
NCT04196491Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- May 2020
- Primary completion
- Jun 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of idecabtagene vicleucel in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoints: Dose-limiting toxicity rates and Adverse Events at 2 years. Started May 2020; status: completed.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04196491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04196491.